New Medicines, Inspired By Protein Communities
Interline Therapeutics is a drug discovery company focused on systematically elucidating protein communities to define molecular mechanisms of disease.
Proteins have generally been studied as isolated entities, but in nature function in protein communities – interconnected networks of dynamic protein interactions. Medical researchers have been limited by an incomplete understanding of how these networks impact common diseases.
Interline is developing a precision medicine platform to map and modulate protein communities, leveraging recent advancements in genomics, proteomics, structural biology and computational chemistry.
Proteins are the proximal translation of genetic information into multidimensional, broadly druggable chemical space. Advances in multiple disciplines are aligning to expose previously hidden dimensions of protein communities in their native context. Interline will use this information to develop new medicines for genetically validated signaling pathways.
Interline has developed a drug discovery platform focused on three essential areas:
Our genomics pipeline prioritizes genetic variants that drive disease by altering protein communities.
We integrate experimental proteomics and machine learning techniques to identify the detailed molecular mechanisms through which genetic variants change protein community dynamics.
Advanced biophysics, structural biology and computational capabilities enable us to discover and characterize drugs that reshape these communities.
“Protein interaction dynamics inform cellular, structural, and evolutionary mechanisms, and are critical to elucidating how genome variation contributes to human health. Broadly linking genomic variation to changes in protein interactions will impact drug discovery by revealing pathways that drive disease progression.”
– Wade Harper
Click to expand a panel.
Founding Scientific Advisors
Memorial Sloan Kettering
Harvard Medical School
University of California San Francisco
Max Planck Institute
previously Roche, Genentech, Pfizer
Board Of Directors
Director and Chairman
Director, Corporate Development
VP, Computational Chemistry
Director, Cell Biology
VP, Discovery Pharmacology
Director Lead Discovery
VP, Medicinal Chemistry
“The reactions of life depend on dynamic protein molecular machines. Modulating the manner in which these machines interact – the key inputs and outputs of protein function – offers tremendous potential for developing new therapies.”
– Brenda Schulman
Interline is creating a culture centered around our dual commitments to patients and employees.
We prioritize science and innovation, empower one another, and are growing a diverse and inclusive team with individuals united by our common values.
For press inquiries click here
Interline Therapeutics Launches With $92 Million to Map and Correct Dysfunctional Protein Communities
May 13, 2021
Foresite, Arch fuel $92M round for Interline Therapeutics, a biotech taking aim at protein communities
May 13, 2021
290 Utah Avenue
South San Francisco, CA
Required fields *